Triglav Investments D.O.O. Decreases Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Triglav Investments D.O.O. cut its Thermo Fisher Scientific stake by 30% in the fourth quarter, selling 6,781 shares and leaving it with 15,814 shares valued at about $9.16 million.
• Insider selling was also reported, including CEO Marc N. Casper’s sale of 5,000 shares and COO Gianluca Pettiti’s sale of 400 shares, both disclosed in SEC filings.
• Thermo Fisher recently beat quarterly earnings and revenue estimates, raised FY2026 guidance to $24.64-$25.12 EPS, and pays a quarterly dividend of $0.47 per share, while analysts currently rate the stock a Moderate Buy with a $616.10 consensus price target.

Triglav Investments D.O.O. lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 30.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,814 shares of the medical research company's stock after selling 6,781 shares during the quarter. Triglav Investments D.O.O.'s holdings in Thermo Fisher Scientific were worth $9,163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. High Note Wealth LLC grew its holdings in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after acquiring an additional 29 shares during the period. JPL Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth $28,000. Beacon Financial Strategies CORP bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $29,000. Olistico Wealth LLC bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $29,000. Finally, Cloud Capital Management LLC bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth $31,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 5,000 shares of the business's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $492.34 on Friday. The stock's 50-day simple moving average is $479.94 and its 200-day simple moving average is $534.64. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The company has a market capitalization of $182.96 billion, a price-to-earnings ratio of 27.07, a PEG ratio of 2.16 and a beta of 0.88. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business's revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the business earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific's payout ratio is currently 10.34%.

Analyst Upgrades and Downgrades

TMO has been the subject of several research analyst reports. DZ Bank started coverage on Thermo Fisher Scientific in a report on Friday, March 27th. They issued a "buy" rating and a $610.00 price objective for the company. Robert W. Baird cut their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a report on Friday, April 24th. Citigroup boosted their price target on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a "buy" rating in a report on Friday, January 30th. UBS Group reissued a "neutral" rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Finally, KeyCorp reissued an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus price target of $616.10.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.